Is PrEP Safe Long-Term? What 14 Years of Real-World Data Actually Shows

Truvada was FDA-approved for PrEP in 2012. We now have 14 years of real-world follow-up across hundreds of thousands of people, plus controlled trials running up to 10+ years. The short answer to "is PrEP safe long-term?" is yes — PrEP is one of the best-studied medications in modern HIV prevention, the side effects are well-characterized, and the serious ones are rare and reversible. Here's what the actual data shows on kidneys, bones, weight, and everything else people worry about.

TL;DR

Most people tolerate PrEP very well. Common early side effects (nausea, headache, fatigue) usually resolve in 4–6 weeks. Kidney and bone effects from TDF-based PrEP (generic/Truvada) are real but small and reversible. Descovy is easier on kidneys and bones but is associated with modest weight gain. Injectables (Apretude, Yeztugo) have different side-effect profiles, mostly mild injection-site reactions. Serious events are rare and usually caught by the quarterly labs your provider orders anyway.

How much data do we actually have?

Sometimes "long-term safety" is hand-waved. In PrEP's case, the data is substantial:

iPrEx (2010, open-label extension through 2015) — the trial that got Truvada approved as PrEP. Tracked thousands of participants across six countries.
PROUD (UK, 2016) — real-world effectiveness trial.
IPERGAY (France, 2015) — established on-demand dosing safety.
DISCOVER (2020) — head-to-head Truvada vs Descovy, ~5,000 participants, 96+ weeks of follow-up.
HPTN 083 & 084 (2021) — cabotegravir (Apretude) injectable trials with thousands of participants.
PURPOSE 1 & 2 (2024) — lenacapavir (Yeztugo) trials in cisgender women and a diverse population.
Kaiser Permanente, CDC, and NHS cohort data — hundreds of thousands of person-years of real-world follow-up.

That's a level of evidence most medications never reach. And because HIV treatment uses the same drugs at the same doses, there's an additional 15+ years of safety data from people living with HIV who've taken tenofovir/emtricitabine continuously — some for two decades.

Common side effects: "start-up syndrome"

Nausea, headache, fatigue, sometimes mild GI upset

Common

About 10–20% of people experience some form of "start-up syndrome" in the first 2–6 weeks on oral PrEP. It feels mild to moderate — think slight queasiness in the morning, a dull headache — and it almost always resolves on its own as your body adjusts. Taking PrEP with food helps. Persistent side effects after 6 weeks are uncommon and worth flagging to your provider.

Kidney function (TDF-based PrEP)

Small reductions in estimated GFR

Reversible

Tenofovir disoproxil fumarate (TDF) — the active ingredient in generic PrEP and Truvada — produces a small decline in kidney function over time. In DISCOVER, TDF recipients saw an average eGFR decline of about 2–5 mL/min over ~2 years. This is usually not clinically meaningful, and it reverses after stopping the medication.

That said, TDF isn't the right choice for everyone. If you have pre-existing chronic kidney disease, hypertension, diabetes, or are over 60, your provider may recommend Descovy or injectable PrEP instead. The quarterly creatinine check that's part of standard PrEP monitoring is specifically designed to catch this early.

Rare serious kidney events (Fanconi syndrome, acute tubular injury)

Very rare

These are uncommon and typically reversible after stopping TDF. Real-world cohort data from Kaiser Permanente found the absolute risk of meaningful kidney injury on PrEP was low — most events occur in people with pre-existing kidney disease or who are on other nephrotoxic medications.

Bone density (TDF-based PrEP)

Small reductions in bone mineral density

Reversible

TDF causes small, measurable reductions in bone mineral density — typically 1–2% in the hip and spine over the first year. This plateaus, and BMD recovers after stopping TDF. Fracture risk has not been shown to be meaningfully increased in PrEP users. For most healthy adults, this side effect is real but not clinically significant.

For teenagers whose bones are still developing, and for older adults with osteoporosis risk, Descovy or injectables may be preferred. Descovy (TAF-based) shows minimal impact on bone density in head-to-head trials.

Weight gain (Descovy)

Modest weight gain, mostly on Descovy and injectables

Common, modest

This is the trade-off. Descovy (TAF-based) is easier on kidneys and bones than TDF — but it's associated with modest weight gain, typically 1–3 kg (~2–6 lbs) over the first year. Generic TDF/Truvada is essentially weight-neutral in PrEP trials.

Cabotegravir (Apretude) is also associated with some weight gain, consistent with the broader integrase inhibitor class. Yeztugo (lenacapavir) data on weight is still emerging.

If weight management is a priority, generic TDF/FTC is the least likely of the oral options to cause it. If kidney or bone health is the priority, Descovy or injectables are the better fit — with the known weight trade-off.

TDF vs TAF vs injectables: side-by-side

Concern	Generic / Truvada (TDF)	Descovy (TAF)	Apretude / Yeztugo (injectable)
Kidney impact	Small decline, reversible	Minimal	Minimal
Bone density	Small reduction, reversible	Minimal	Minimal
Weight	Weight-neutral	Modest gain (1–3 kg)	Some weight gain reported
GI side effects	More common early on	Less common	N/A (not oral)
Injection site reactions	N/A	N/A	Common, mild, transient
Cost (cash, uninsured)	~$30/month retail	~$2,200/month retail	~$22,000–$28,218/year retail

Worried about side effects? A consult is free.

MISTR prescribers can walk you through which PrEP option fits your health profile — kidney function, bone health, weight goals, and lifestyle. The whole process (consult, labs, medication) is $0 in all 50 states, insured or uninsured.

Use code: ANDR735

Using this code helps keep FreePrEP.org running and connects more people to free PrEP.

Talk to a MISTR Provider →

What about mental health, mood, and neuropsychiatric effects?

Oral TDF/FTC (generic, Truvada, Descovy) has no meaningful signal for depression, anxiety, or neuropsychiatric effects in trial data. Cabotegravir (Apretude) is an integrase inhibitor, and this class has rare reports of insomnia or mood changes in HIV treatment — but these are uncommon at PrEP doses. Yeztugo (lenacapavir) acts through a different mechanism (capsid inhibition) and has not shown neuropsychiatric signals in trials.

Liver effects

Both TDF/FTC and TAF/FTC are also approved for treating chronic hepatitis B. If you have hepatitis B, do not stop PrEP abruptly without first consulting a hepatologist, because stopping can cause a hepatitis B flare. This is why baseline hepatitis B testing is part of PrEP workup. Otherwise, liver effects of PrEP are minimal and liver-function tests aren't routinely required (though many providers check annually).

What does quarterly monitoring look like?

If you're on PrEP, you'll have routine labs every 3 months. This is specifically designed to catch any of the above concerns early. A typical quarterly visit includes:

HIV test — to confirm you're still negative (PrEP requires HIV-negative status).
Serum creatinine — to track kidney function.
STI screening — because PrEP prevents HIV but not other STIs.
Pregnancy test (when applicable).
A brief check-in on side effects and adherence.

All of this is covered at $0 under the ACA if you have commercial insurance, and telehealth platforms like MISTR handle it automatically for insured and uninsured patients in all 50 states.

The risk nobody talks about: not taking PrEP

Every discussion of PrEP side effects should be balanced against the baseline — untreated HIV, which is life-altering. PrEP reduces the risk of HIV acquisition by 99%+ when taken as prescribed. For anyone at meaningful risk, the math overwhelmingly favors being on PrEP. Long-term HIV medication is also very safe, but avoiding HIV in the first place is better.

What if I want to stop PrEP?

Stopping PrEP is straightforward for most people. A few guidelines:

Take oral PrEP for at least 7 days after your last potential exposure before stopping (for anal sex) or at least 28 days (for vaginal sex), per CDC guidance.
If you have hepatitis B, don't stop abruptly — talk to your provider first.
Injectables have a long "tail." After your last Apretude shot, drug levels decline slowly over ~12 months. During that period, drug is present but not at protective concentrations. If you stop injectable PrEP, bridge with oral PrEP until your provider clears you.
Any side effects from PrEP typically resolve within weeks of stopping.

Wondering which PrEP is right for you?

Use the eligibility tool — four questions, 60 seconds. We'll match you with every free PrEP option available, along with which might fit your health profile best.

Start the Eligibility Tool →

Bottom line

PrEP is one of the most carefully studied preventive medications in modern medicine. The side effects are real but mostly minor and manageable, the serious ones are rare and reversible, and the quarterly monitoring is designed to catch problems early. For almost anyone at meaningful risk of HIV, the benefits of PrEP vastly outweigh the side-effect profile — and you have enough options (TDF, TAF, every-two-months injectable, twice-yearly injectable) that you can pick one that fits your body and preferences.

If you're hesitating to start PrEP because of side-effect worries, the honest answer is: start with a consultation. Most people tolerate PrEP very well, and if the first option doesn't work for you, switching is easy.

Ready to start PrEP?

MISTR covers medication, labs, and provider consults at $0 in all 50 states. If your first option doesn't feel right, switching formulations is easy. First prescription typically arrives in 24–48 hours.